Abstract
Chromatography has been a mainstay in the downstream processing and purification of biopharmaceutical medicines. Until now, this has largely involved the purification of protein products such as recombinant enzymes and monoclonal antibodies using large-scale column chromatography methods. The development of advanced therapeutic medicinal products (ATMP) is heralding in a new era of therapeutics for a range of indications. These new therapeutics use diverse substances ranging from live stem cell preparations to fragments of nucleic acid enclosed in a viral delivery system. With these new technologies come new challenges in their purification. In this chapter, the challenges faced in producing and purifying viral vectors capable of delivering life-altering gene therapy to the patient will be discussed. Current methods of chromatography capable of adaptation to meet these new challenges and advancements that may be needed to increase the purification capabilities for these new products will also be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
EMA. Advanced therapy medicinal products: overview. 15 Dec 2021. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview
EMA (2021) Luxturna. Cited 15 Dec 2021. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna
EMA (2020) First CAR-T cell medicine for mantle cell lymphoma. 16/10/2020. Cited 2021. Available from: https://www.ema.europa.eu/en/news/first-car-t-cell-medicine-mantle-cell-lymphoma
Grimm D, Kleinschmidt JA (1999) Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther 10(15):2445–2450
Mietzsch M et al (2020) Characterization of AAV-specific affinity ligands: consequences for vector purification and development strategies. Mol Ther Methods Clin Dev 19:362–373
Berns KI (1990) Parvovirus replication. Microbiol Rev 54(3):316–329
Kotin RM, Linden RM, Berns KI (1992) Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 11(13):5071–5078
Kotin RM et al (1990) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 87(6):2211–2215
Duan D et al (1998) Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72(11):8568–8577
Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72(3):2224–2232
Burova E, Ioffe E (2005) Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther 12(S1):S5–S17
Green M et al (1967) Adenovirus DNA. I. Molecular weight and conformation. Proc Natl Acad Sci U S A 57(5):1302–1309
Anguela XM, High KA (2019) Entering the modern era of gene therapy. Annu Rev Med 70(1):273–288
Bryson PD, Wang P (2014) Chapter 24 – lentivector vaccines. In: Lattime EC, Gerson SL (eds) Gene therapy of cancer, 3rd edn. Academic Press, San Diego, pp 345–361
Naldini L et al (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci 93(21):11382–11388
Naldini L et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263–267
Schambach A, Baum C (2008) Clinical application of lentiviral vectors – concepts and practice. Curr Gene Ther 8(6):474–482
Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1(1):241–245
Higashikawa F, Chang L (2001) Kinetic analyses of stability of simple and complex retroviral vectors. Virology 280(1):124–131
Coroadinha AS et al (2006) Effect of medium sugar source on the production of retroviral vectors for gene therapy. Biotechnol Bioeng 94(1):24–36
Coroadinha AS et al (2006) Effect of osmotic pressure on the production of retroviral vectors: enhancement in vector stability. Biotechnol Bioeng 94(2):322–329
Beer C et al (2003) The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. Virology 308(1):137–146
Carmo M et al (2008) From retroviral vector production to gene transfer: spontaneous inactivation is caused by loss of reverse transcription capacity. J Gene Med 10(4):383–391
Potter M et al (2002) Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors. In: Phillips MI (ed) Methods in enzymology. Academic Press, San Diego, pp 413–430
Zolotukhin S et al (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6(6):973–985
Zolotukhin S et al (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28(2):158–167
Peng HH et al (2006) A rapid and efficient method for purification of recombinant adenovirus with arginine–glycine–aspartic acid-modified fibers. Anal Biochem 354(1):140–147
Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15(11):840–848
Auricchio A et al (2001) Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 12(1):71–76
Moreira AS et al (2021) Advances in lentivirus purification. Biotechnol J 16(1):2000019
Fortuna AR et al (2018) Optimization of cell culture-derived influenza A virus particles purification using sulfated cellulose membrane adsorbers. Eng Life Sci 18(1):29–39
Pillay TS, Muyldermans S (2021) Application of single-domain antibodies (“nanobodies”) to laboratory diagnosis. Ann Lab Med 41(6):549–558
Penaud-Budloo M et al (2018) Pharmacology of recombinant adeno-associated virus production. Mol Ther Methods Clin Dev 8:166–180
Huyghe BG et al (1995) Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 6(11):1403–1416
Blanche F et al (2000) An improved anion-exchange HPLC method for the detection and purification of adenoviral particles. Gene Ther 7(12):1055–1062
Stewart PL, Burnett RM (1995) Adenovirus structure by X-ray crystallography and electron microscopy. In: Doerfler W, Böhm P (eds) The molecular repertoire of adenoviruses I: virion structure and infection. Springer Berlin Heidelberg, Berlin, Heidelberg, pp 25–38
Schweizer M, Merten OW (2010) Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther 10(6):474–486
Rodrigues T et al (2006) Screening anion-exchange chromatographic matrices for isolation of onco-retroviral vectors. J Chromatogr B 837(1):59–68
Merten OW et al (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22(3):343–356
Qu G et al (2007) Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods 140(1):183–192
Smith RH, Ding C, Kotin RM (2003) Serum-free production and column purification of adeno-associated virus type 5. J Virol Methods 114(2):115–124
Gagnon P (2010) Monoliths open the door to key growth sectors. BioProcess Int 8(10):20–23
Barut M et al (2005) Convective interaction media short monolithic columns: enabling chromatographic supports for the separation and purification of large biomolecules. J Sep Sci 28(15):1876–1892
Jungbauer A, Hahn R (2008) Polymethacrylate monoliths for preparative and industrial separation of biomolecular assemblies. J Chromatogr A 1184(1):62–79
Ramos-de-la-Peña AM, González-Valdez J, Aguilar O (2019) Protein A chromatography: challenges and progress in the purification of monoclonal antibodies. J Sep Sci 42(9):1816–1827
Charcosset C (2012) 5 – Membrane chromatography. In: Charcosset C (ed) Membrane processes in biotechnology and pharmaceutics. Elsevier, Amsterdam, pp 169–212
Challener CA (2021) Single-use technologies prove effective for viral vector process development. Cited 2021. Available from: http://www.processdevelopmentforum.com/articles/single-use-technologies-prove-effective-for-viral-vector-process-development/
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kearney, A.M. (2023). Chromatographic Purification of Viral Vectors for Gene Therapy Applications. In: Loughran, S.T., Milne, J.J. (eds) Protein Chromatography. Methods in Molecular Biology, vol 2699. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3362-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3362-5_4
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3361-8
Online ISBN: 978-1-0716-3362-5
eBook Packages: Springer Protocols